-
Mar 27, 2025 | 
cambridge.org | Howard Bauchner |Robert Steinbrook |Rita F. Redberg
Hostname: page-component-5cf477f64f-2wr7h Total loading time: 0 Render date: 2025-04-02T13:35:00.398Z Has data issue: false hasContentIssue false Published online by Cambridge University Press: 27 March 2025 Howard Bauchner [Opens in a new window] , Show author details Keywords researchmisconductscientific misconductjournals and research misconduct Type Symposium Information Journal of Law, Medicine & Ethics , First View , pp.
-
Mar 12, 2025 | 
bmj.com | Alexander O. Everhart |Pinar Karaca-Mandic |Rita F. Redberg |Joseph Ross
Research BMJ 2025; 388 doi: https://doi.org/10.1136/bmj-2024-081518 Cite this as: BMJ 2025;388:e081518 Alexander O Everhart, instructor1 2, Pinar Karaca-Mandic, professor3, Rita F Redberg, professor4 5, Joseph S Ross, professor6 7 8, Sanket S Dhruva, associate professor9 10 11 1Division of General Medical Sciences, John T Milliken Department of Medicine, Washington University School of Medicine in St Louis, St Louis, MO, USA 2Center for Advancing Health Services, Policy and Economics...
-
Feb 12, 2025 | 
jamanetwork.com | Donald M. Lloyd-Jones |Sadiya Khan |Maryanne Demasi |Rita F. Redberg
Statins for Primary Prevention of Cardiovascular Disease—Reply In Reply We thank Dr Demasi and colleagues for sharing their perspectives. We judge that the statements we made are supported by the evidence and we stand by the rationale presented and the conclusions expressed in our Viewpoint. As we discussed, data from randomized clinical trials show net benefit of statin therapy for patient groups with 10-year major cardiovascular event rates as low as 3%.
-
Feb 12, 2025 | 
jamanetwork.com | Rita F. Redberg |John Abramson |James A. Diao |Venkatesh L. Murthy
Statins for Primary Prevention of Cardiovascular Disease Statin and Antihypertensive Therapy Eligibility With the PREVENT Cardiovascular Risk Equations James A. Diao, MD, MPhil; Ivy Shi, MD; Venkatesh L. Murthy, MD, PhD; Thomas A. Buckley, BS; Chirag J. Patel, PhD; Emma Pierson, PhD; Robert W. Yeh, MD, MSc; Dhruv S. Kazi, MD, MS; Rishi K. Wadhera, MD, MPP, MPhil; Arjun K.
-
Nov 15, 2024 | 
jamanetwork.com | Joshua M. Hauser |Rita F. Redberg |Ali Abbasi
To the Editor Robust and high-quality evidence generation for new drugs and devices benefits many parties. Ensuring that this evidence proves that treatments are beneficial is essential. As our health care system operates like a speeding train with no brakes immediately following US Food and Drug Administration (FDA) approval, reasonable evidence that benefits exceed harms must be obtained before approval.
-
Jun 13, 2024 | 
jamanetwork.com | Allison Kratka |Rita F. Redberg |Robert W. Yeh |Richard A Shlofmitz
Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent Restenosis Robert W. Yeh, MD, MSc; Richard Shlofmitz, MD; Jeffrey Moses, MD; William Bachinsky, MD; Suhail Dohad, MD; Steven Rudick, MD; Robert Stoler, MD; Brian K. Jefferson, MD; William Nicholson, MD; John Altman, MD; Cinthia Bateman, MD; Amar Krishnaswamy, MD; J. Aaron Grantham, MD; Frank J. Zidar, MD; Steven P. Marso, MD; Jennifer A. Tremmel, MD, MS; Cindy Grines, MD; Mustafa I. Ahmed, MD; Azeem Latib, MD; Behnam Tehrani, MD; J.
-
Jun 11, 2024 | 
statnews.com | Sanket S Dhruva |Rita F. Redberg
Multi-cancer early detection tests (MCEDs), sometimes called liquid biopsy tests, are a new method of detecting cancer early. While the concept is promising, these untested tests currently pose significant problems. MCEDs look for circulating DNA or cells from cancers. The goal is to detect cancer in its earliest stages in people without any signs or symptoms of the disease.
-
Jun 10, 2024 | 
jamanetwork.com | Jessica N. Holtzman |Rita F. Redberg
The safety and effectiveness of high-risk medical devices, such as transcatheter valves, neuromuscular stimulators, and orthopedic implants, warrant rigorous review. For more than 4 decades, the US Food and Drug Administration (FDA) has played the central role of evaluating the effectiveness of novel tests, drugs, and medical devices. The FDA’s purpose is to protect the public from unnecessary harm.
-
May 16, 2024 | 
onlinelibrary.wiley.com | Renee Y. Hsia |Rita F. Redberg |Yu-Chu Shen
INTRODUCTION American health care is not immune to the popular cultural concept that “more is better.” Studies have shown that some health care services have led to overdiagnosis and overtreatment, resulting in wasteful spending1-3 and potential harm.4-7 In cardiac care, for example, many notable advances have improved the overall expansion of services, but prior literature has found that these services tend to be unequally distributed across communities.8, 9 Herein we explored the impact of...
-
Aug 28, 2023 | 
jamanetwork.com | Sanket S Dhruva |Rebecca Smith-Bindman |Rita F. Redberg
The Need for Randomized Clinical Trials Demonstrating Reduction in All-Cause Mortality With Blood Tests for Cancer Screening In recent years, blood tests that look for circulating tumor DNA and biomarkers (termed liquid biopsies) have been developed. As Carr and Welch describe in this issue of JAMA Internal Medicine,1 these tests are being explored for diagnosis of suspected cancer, cancer surveillance after treatment, response to therapy, and chemotherapeutic selection.
